There is a growing amount of evidence that brachytherapy’s role as a prostate cancer treatment modality should not be limited to low-risk cases, but should also include patients with higher risk disease. The Journal of Clinical Oncology recently reported on an...
Earlier this month, a retrospective study of prostate cancer patients with Gleason scores of 9-10 published online by the Journal of the American Medical Association concluded the following: “Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT...
Brachytherapy treatment for prostate cancer is not a new venture to many clinicians. However, new, groundbreaking data is here to shed light on how brachytherapy is significantly improving patient outcomes. ASCENDE-RT is the first ever controlled, randomized trial to...
In recent phase 3 clinical research, findings suggest that prostate cancer patients treated with brachytherapy alone receive similar outcomes to patients who received brachytherapy with additional external radiation. These findings are among recent data that show the...
In recent news, the University of Michigan has opened the first prostate cancer risk clinic in the nation. The clinic aims to monitor and identify the risk of prostate in cancer in men with genetic predisposition to the disease through increased screening methods and...